Amicus Therapeutics (NASDAQ:FOLD) Lowered to “Hold” Rating by StockNews.com

Amicus Therapeutics (NASDAQ:FOLD) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

FOLD has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Trading Down 2.9 %

FOLD stock opened at $9.56 on Thursday. Amicus Therapeutics has a 1-year low of $8.78 and a 1-year high of $14.02. The firm has a market cap of $2.86 billion, a P/E ratio of -28.12, a P/E/G ratio of 1.63 and a beta of 0.61. The business’s 50 day moving average is $9.58 and its 200-day moving average is $10.42. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $59,000. Neo Ivy Capital Management lifted its stake in shares of Amicus Therapeutics by 501.6% in the 4th quarter. Neo Ivy Capital Management now owns 395,745 shares of the biopharmaceutical company’s stock valued at $3,727,000 after purchasing an additional 329,959 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Amicus Therapeutics by 96.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 958,671 shares of the biopharmaceutical company’s stock valued at $9,031,000 after purchasing an additional 471,902 shares during the period. Vestal Point Capital LP acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $31,557,000. Finally, Sovereign s Capital Management LLC acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $2,806,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.